FDA Approves Osimertinib for Adjuvant EGFR-Mutated Lung Cancer

Published by W Butcher on

The FDA has approved the use of osimertinib as a treatment for patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). According to a release from the manufacturer, the approval is for patients who have had tumor resection with curative intent and was made under the Real-Time Oncology Review pilot program. Osimertinib is also approved for patients whose tumors have exon 19 deletions or exon 21 L858R mutations, the release noted.

Read More…

Categories: Uncategorized